Literature DB >> 23633404

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Surender Khurana1, Jian Wu, Milena Dimitrova, Lisa R King, Jody Manischewitz, Barney S Graham, Julie E Ledgerwood, Hana Golding.   

Abstract

DNA priming improves the response to inactivated influenza A(H5N1) vaccination. We compared the immunogenicity of an H5 DNA prime (using strain A/Indonesia/5/2005) followed by an H5N1 monovalent inactivated vaccine boost at 4, 8, 12, 16, or 24 weeks to that of 2 doses of H5N1 monovalent inactivated vaccine in adults. Antibody epitope repertoires were elucidated by genome-fragment phage-display library analysis, and antibody avidities for HA1 and HA2 domains were measured by surface plasmon resonance. H5 DNA priming expanded the H5-specific antibody epitope repertoire and enhanced antibody avidity to the HA1 (but not the HA2) domain in an interval-dependent manner. Enhanced HA1 binding and avidity after an interval of ≥12 weeks between prime and boost correlated with improved neutralization of homologous and heterologous H5N1 strains. Clinical trials registration NCT01086657.

Entities:  

Keywords:  H5N1; Phage display; SPR; affinity; antibody; epitope; hemagglutinin; immune response; influenza; vaccine; virus

Mesh：

Substances：

Year:  2013        PMID： 23633404      PMCID： PMC3699004          DOI： 10.1093/infdis/jit178

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.

Authors:  Surender Khurana; Nitin Verma; Jonathan W Yewdell; Anne Katrin Hilbert; Flora Castellino; Maria Lattanzi; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Authors:  Chih-Jen Wei; Jeffrey C Boyington; Patrick M McTamney; Wing-Pui Kong; Melissa B Pearce; Ling Xu; Hanne Andersen; Srinivas Rao; Terrence M Tumpey; Zhi-Yong Yang; Gary J Nabel
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

3.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Authors:  Grazia Galli; Duccio Medini; Erica Borgogni; Luisanna Zedda; Monia Bardelli; Carmine Malzone; Sandra Nuti; Simona Tavarini; Chiara Sammicheli; Anne K Hilbert; Volker Brauer; Angelika Banzhoff; Rino Rappuoli; Giuseppe Del Giudice; Flora Castellino
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

5.  Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Authors:  Surender Khurana; Christopher Larkin; Swati Verma; Manju B Joshi; Juan Fontana; Alasdair C Steven; Lisa R King; Jody Manischewitz; William McCormick; Rajesh K Gupta; Hana Golding
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

6.  Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Authors:  Surender Khurana; Wanida Chearwae; Flora Castellino; Jody Manischewitz; Lisa R King; Agnieszka Honorkiewicz; Michael T Rock; Kathryn M Edwards; Giuseppe Del Giudice; Rino Rappuoli; Hana Golding
Journal:  Sci Transl Med       Date:  2010-01-20       Impact factor: 17.956

7.  Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

8.  Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Authors:  Surender Khurana; Swati Verma; Nitin Verma; Corey J Crevar; Donald M Carter; Jody Manischewitz; Lisa R King; Ted M Ross; Hana Golding
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

9.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.

Authors:  Ana Clara Monsalvo; Juan P Batalle; M Florencia Lopez; Jens C Krause; Jennifer Klemenc; Johanna Zea Hernandez; Bernardo Maskin; Jimena Bugna; Carlos Rubinstein; Leandro Aguilar; Liliana Dalurzo; Romina Libster; Vilma Savy; Elsa Baumeister; Liliana Aguilar; Graciela Cabral; Julia Font; Liliana Solari; Kevin P Weller; Joyce Johnson; Marcela Echavarria; Kathryn M Edwards; James D Chappell; James E Crowe; John V Williams; Guillermina A Melendi; Fernando P Polack
Journal:  Nat Med       Date:  2010-12-05       Impact factor: 53.440

10.  Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets.

Authors:  Surender Khurana; Amorsolo L Suguitan; Yonaira Rivera; Cameron P Simmons; Antonio Lanzavecchia; Federica Sallusto; Jody Manischewitz; Lisa R King; Kanta Subbarao; Hana Golding
Journal:  PLoS Med       Date:  2009-04-21       Impact factor: 11.069
View more
  35 in total

1.  Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Authors:  Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham
Journal:  Contemp Clin Trials       Date:  2015-08-12       Impact factor: 2.226

2.  A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Authors:  Kawsar R Talaat; Catherine J Luke; Surender Khurana; Jody Manischewitz; Lisa R King; Bridget A McMahon; Ruth A Karron; Kristen D C Lewis; Jing Qin; Dean A Follmann; Hana Golding; Kathleen M Neuzil; Kanta Subbarao
Journal:  J Infect Dis       Date:  2014-03-05       Impact factor: 5.226

3.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Authors:  Michela Brazzoli; Diletta Magini; Alessandra Bonci; Scilla Buccato; Cinzia Giovani; Roland Kratzer; Vanessa Zurli; Simona Mangiavacchi; Daniele Casini; Luis M Brito; Ennio De Gregorio; Peter W Mason; Jeffrey B Ulmer; Andrew J Geall; Sylvie Bertholet
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

4.  Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies.

Authors:  Surender Khurana; Sandra Fuentes; Elizabeth M Coyle; Supriya Ravichandran; Richard T Davey; John H Beigel
Journal:  Nat Med       Date:  2016-10-31       Impact factor: 53.440

5.  H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem.

Authors:  Adam K Wheatley; James R R Whittle; Daniel Lingwood; Masaru Kanekiyo; Hadi M Yassine; Steven S Ma; Sandeep R Narpala; Madhu S Prabhakaran; Rodrigo A Matus-Nicodemos; Robert T Bailer; Gary J Nabel; Barney S Graham; Julie E Ledgerwood; Richard A Koup; Adrian B McDermott
Journal:  J Immunol       Date:  2015-06-15       Impact factor: 5.422

6.  Identification of Aim2 as a sensor for DNA vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

7.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Authors:  M Gordon Joyce; Adam K Wheatley; Paul V Thomas; Gwo-Yu Chuang; Cinque Soto; Robert T Bailer; Aliaksandr Druz; Ivelin S Georgiev; Rebecca A Gillespie; Masaru Kanekiyo; Wing-Pui Kong; Kwanyee Leung; Sandeep N Narpala; Madhu S Prabhakaran; Eun Sung Yang; Baoshan Zhang; Yi Zhang; Mangaiarkarasi Asokan; Jeffrey C Boyington; Tatsiana Bylund; Sam Darko; Christopher R Lees; Amy Ransier; Chen-Hsiang Shen; Lingshu Wang; James R Whittle; Xueling Wu; Hadi M Yassine; Celia Santos; Yumiko Matsuoka; Yaroslav Tsybovsky; Ulrich Baxa; James C Mullikin; Kanta Subbarao; Daniel C Douek; Barney S Graham; Richard A Koup; Julie E Ledgerwood; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola; Adrian B McDermott
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

8.  A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.

Authors:  John J Suschak; Shixia Wang; Katherine A Fitzgerald; Shan Lu
Journal:  J Immunol       Date:  2015-11-20       Impact factor: 5.422

9.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Authors:  Joyce K Hu; Jordan C Crampton; Albert Cupo; Thomas Ketas; Marit J van Gils; Kwinten Sliepen; Steven W de Taeye; Devin Sok; Gabriel Ozorowski; Isaiah Deresa; Robyn Stanfield; Andrew B Ward; Dennis R Burton; Per Johan Klasse; Rogier W Sanders; John P Moore; Shane Crotty
Journal:  J Virol       Date:  2015-08-05       Impact factor: 5.103

Review 10.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.